C5 complement inhibition and FcRn modulation in generalized myasthenia gravis. Fast-acting but short-lived therapies the use of which should prompt assertive escalation of conventional treatments
Open Access
- 11 January 2025
- journal article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (4) , 309
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- C5 complement inhibition and FcRn modulation in generalized myasthenia gravis. Fast-acting but short-lived therapies the use of which should prompt assertive escalation of conventional treatmentsJournal of Neurology, Neurosurgery & Psychiatry, 2025
- C5 complement inhibition versus FcRn modulation in generalised myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2025
- The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndromeClinical and Experimental Neuroimmunology, 2023
- Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia GravisJAMA Neurology, 2022
- Randomized Trial of Thymectomy in Myasthenia GravisNew England Journal of Medicine, 2016
- Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune DiseasesNew England Journal of Medicine, 1999